A Deal Taking Shape
Reuters reported last month that Blackstone was exploring a sale of ZO Skin Health with investment banks Citigroup and Raymond James. The firm acquired ZO in 2020 through its tactical opportunities fund, and a price of around $1.5 billion suggests the market values the brand highly.
The deal is still based on information from sources and has not been officially confirmed by the parties. Even so, it fits the strategy Galderma has pursued in recent years: adding scientifically grounded brands to an already diverse portfolio.
Galderma's Growing Portfolio
Founded in 1981, Galderma owns a range of familiar names in dermatology and aesthetics:
The Cetaphil and Alastin Skincare lines.
The acne gels Differin and Epiduo.
The injectable neurotoxin Dysport and the dermal filler Restylane.













